---
title: "426CVR015TMP.US (426CVR015TMP.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/426CVR015TMP.US/news.md"
symbol: "426CVR015TMP.US"
name: "426CVR015TMP.US"
parent: "https://longbridge.com/zh-HK/quote/426CVR015TMP.US.md"
datetime: "2026-03-15T00:00:11.763Z"
locales:
  - [en](https://longbridge.com/en/quote/426CVR015TMP.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/426CVR015TMP.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/426CVR015TMP.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/426CVR015TMP.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/426CVR015TMP.US/news.md)


# 426CVR015TMP.US (426CVR015TMP.US) — 相關新聞

### [Hemostemix Leadership Attending Abundance360 Summit | HMTXF Stock News](https://longbridge.com/zh-HK/news/278416203.md)
*2026-03-09T07:23:00.000Z*
> Hemostemix Inc. (TSXV: HEM) announced that CEO Thomas Smeenk and Chairman Peter Lacey are attending the 2026 Abundance36

### [Psychedelic biotechs are moving towards Phase 3 with five companies advancing CNS treatments for depression and anxiety.](https://longbridge.com/zh-HK/news/277230596.md)
*2026-02-27T16:46:40.000Z*
> Psychedelic biotechs are advancing towards Phase 3 trials, with five companies focusing on CNS treatments for depression

### [Hemogenyx Raises £2.5m to Advance CAR-T Trials in Adult and Pediatric AML](https://longbridge.com/zh-HK/news/275486211.md)
*2026-02-10T15:57:22.000Z*
> HemoGenyx Pharmaceuticals has raised £2.5 million from private investors through a direct subscription for new shares, f

### [Hemostemix Partners with First Nations to Establish Healthcare Centres](https://longbridge.com/zh-HK/news/274668429.md)
*2026-02-03T13:56:03.000Z*